Drug Profile

ARG 301

Alternative Names: APL-A12; ARG301

Latest Information Update: 02 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Memphis VA Medical Center; University of Tennessee
Developer arGentis Pharmaceuticals; Memphis VA Medical Center; University of Tennessee
Class Antirheumatics; Peptides
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Rheumatoid arthritis

Most Recent Events

28 Apr 2018 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in USA (PO)
06 Apr 2016 Phase I development is ongoing in USA
17 Nov 2009 Phase-I clinical trials in Rheumatoid arthritis in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com